A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
Phase of Trial: Phase III
Latest Information Update: 12 Sep 2014
At a glance
- Drugs Perampanel (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Registrational
- Sponsors Eisai Co Ltd; Eisai Inc
- 10 Sep 2009 Planned end date (Apr 2008) added as reported by ClinicalTrials.gov.
- 10 Apr 2008 Status changed from recruiting to discontinued.
- 21 Aug 2007 New trial record.